Opteev Develops World's First Multiplex Biochip That Precisely Identifies Covid, Flu, Rsv, And Respiratory Pathogens In Under 1 Minute

By Author: Arina Smith
Total Articles: 185
Comment this article

Opteev Technologies, Inc., a leading diagnostics technology company, has filed a patent (Patent Application #63/513,007) for a revolutionary multiplex biochip designed for respiratory infection diagnostics. This groundbreaking polymer-based biochip has the capability to test for multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and can precisely identify the specific virus or bacteria in less than 1 minute. This technology promises to create an ultra-rapid, portable, and accurate syndromic diagnostic device that empowers healthcare providers with immediate results.

The tiny biochip can directly detect whole viruses in real-time in both processed and unprocessed samples, such as saliva or nasal swabs, and has demonstrated an unprecedented accuracy rate of 99.49% during its analytical performance evaluation. The biosensor achieves fine-tuned specificity by carefully selecting specific virus-binding peptides, enabling accurate identification of target viruses in complex samples. To ensure precise and reliable virus detection, the biochip utilizes artificial intelligence ...
... to optimize the frequency range, effectively mitigating the impact of interfering noise signals.

Unlike conventional respiratory panels that are costly and time-consuming, Opteev's multiplex biochip offers affordable syndromic testing for healthcare providers, with the ability to process samples at the point of care. This enables simultaneous detection and specific identification of multiple pathogens instantaneously, eliminating the need for speculation and providing critical information for delivering the most effective treatment options at the point of care.

Dr. Mesfin Meshesha, Vice President of Virology & Diagnostics at Opteev Technologies, expressed excitement about the potential of this technology to transform patient care, streamline operations, and reduce costs. As Opteev Technologies continues to push the boundaries of point-of-care diagnostics, the company is open to potential collaborations and partnerships to further develop and commercialize its multiplex biochip.

Conrad Bessemer, Opteev's Chairman and Co-founder, emphasized the massive potential of their game-changing multiplex biochip and invites collaboration to shape the future of diagnostics.

Opteev Technologies, headquartered in Baltimore, MD, is a pioneering technology company at the forefront of diagnostics, with a strong focus on respiratory pathogen detection. As a subsidiary of Novatec, Inc., a trusted manufacturer and supplier of machinery and sensor technology, Opteev leverages decades of experience to drive advancements in healthcare.

For more information about Opteev Technologies and its groundbreaking multiplex biochip, interested parties can visit the company's website at www.opteev.com.

https://www.techdogs.com/tech-news/pr-newswire/opteev-develops-worlds-first-multiplex-biochip-that-precisely-identifies-covid-flu-rsv-and-respiratory-pathogens-in-under-1-minute